Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis
Sponsored by Jinnah Postgraduate Medical Centre
About this trial
Last updated 2 years ago
Study ID
NO.F.2-81/2022-GENL/251/JPMC
Status
Completed
Type
Interventional
Phase
N/A
Placebo
No
Accepting
30 to 50 Years
All
Trial Timing
Ended 2 years ago
What is this trial about?
Psoriasis is a serious, immune-driven illness that affects around 2% of the population and
has a wide range of clinical manifestations 1-3 . Many patients have localized illness, and
topical therapy can be an important part of treatment.
tazarotene is the first receptor-selective retinoid for the topical treatment of plaque
psoriasis. On application, tazarotene is rapidly hydrolyzed to its main metabolite,
tazarotenic acid, which binds to retinoic acid receptors (RARs) in the nucleus. Tazarotenic
acid selectively binds to RARs b and g . The predominant type of RAR expressed in the human
epidermis is RAR, indicating that it may be an important mediator of retinoid action in skin.
.
What are the participation requirements?
Inclusion Criteria
- Patients between 30-50 years of age, either gender presenting with scalp psoriasis as per operational definition will be included in the study.
Exclusion Criteria
- pustular psoriasis or had used phototherapy, photochemotherapy, or systemic psoriasis therapy within the last four weeks (or biologics within the last three months).
- Used topical treatment within 14 days prior to the baseline visit or who were diagnosed with skin conditions that would interfere with the interpretation of results were also excluded. pregnant women, women attempting to become pregnant, lactation